Latest Conference

Investigators found increased mortality in the combination arm where 21% of patients died vs 16% in the standard therapy arm, although the number of patients with persistent bacteremia at day 5 in the combination arm was significantly reduced compared with standard therapy.

A study found that the molecule, Compound A, has potent activity against Acinetobacter Pneumonia in mice possibly by a dual killing mechanism and by reducing lipopolysaccharide-induced vascular leak.

Rezafungin achieved greater and more prolonged penetration at sites of intra-abdominal candidiasis than micafungin, which correlates with significantly greater activity against FKS-mutant Candida glabrata clinical strains.

A study found that eracavycline was 2-4-fold more active than tigecycline against isolates that produced ESBL and at least 8-fold more active than tigecycline against A baumannii.

Melanie Nicol, PharmD, PhD, explores how DMPA hormonal contraception affects women's HIV risk.

Investigators detail the activity of cefiderocol, a novel parenteral siderophore cephalosporin, against carbapenem-resistant clinical isolates.

An Italian study found that immunization rates are high among health workers, but an important proportion of employees are not immune to mumps.

In a study of hospitalized patients across Europe, oritavancin (MIC50/MIC90, 0.03/0.06 mg/L) inhibited all S aureus isolates at ≤0.12 mg/L (susceptible breakpoint).

Ignacio Martin-Loeches, MD, PhD, discusses the efficacy outcomes of the ASPECT-NP trial evaluating ceftolozane/tazobactam for the treatment of nosocomial pneumonia.

What is the key to success that helped a Spanish hospital achieve an 80% reduction in global incidence of catheter-related bloodstream infections and sustain it over an 8-year period?

Jose Arribas, MD, discusses the challenges in the field of long-acting injectable therapy for the treatment, management, and even prevention of HIV.

A large percentage (96%) of health care worker respondents reported feeling confident in their knowledge of antibiotic resistance, but only 60% answered the 7 key questions correctly.

In a symposium at ECCMID 2019, Giovanni Rezza, MD, highlighted the growth of tropical outbreaks occurring in Europe and discussed how warmer temperatures may lead to more frequent tropical outbreaks.

After receiving treatment with ibrexafungerp, a patient with esophageal candidiasis gradually improved and by day 54 he was completely asymptomatic.

Investigators on the CapU3 study concluded that urinary HPV testing may be a good alternative to Pap smear for some women.

An 18-year retrospective cohort study of 130 hospitals in the US Veterans Health Administration system revealed a significant reduction in cases of hospital-onset candidemia. But what caused the drop?

A new study has uncovered that only one-third of patients who present to the emergency department with suspected UTI have evidence of infection, yet the majority receive antibiotics.

MDROs were detected in 334 (22%) curtain cultures from 6 skilled nursing facilities in southeast Michigan.

Subcutaneous implants are 1 promising strategy to address suboptimal adherence to pre-exposure prophylaxis (PrEP) for HIV, and a recent in silico simulation examined pharmacokinetic profiles and safety of tenofovir alafenamide implants.

Brian Woodfall, MD, discusses how long-acting injectables offer a new treatment option for patients with HIV in terms of long-term therapy.

Paul Sax, MD, names the DISCOVER study as one of the highlights of CROI 2019.

Saye Khoo, MD, advocates for a more appropriate, stratified, risk-based approach to prescribing dolutegravir in pregnant women.

Contagion® will be heading to Amsterdam, Netherlands, on Saturday, April 13, 2019, to report on the annual European Congress of Clinical Microbiology and Infectious Diseases conference.

Bluma Brenner, PhD, explains the driving factors behind the push for new antiretroviral drugs for HIV treatment.

Brian Woodfall, MD, shares his opinion on some of the biggest advancements in HIV treatment and prevention.

Paul Sax, MD, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.

Susan Swindells, MBBS, provides an overview of long-acting injectable cabotegravir + rilpivirine for clinicians.

Karin Bosh, PhD, explains why the opioid overdose death rate was higher in 2015 than in 2011 among people with HIV.

PrEP isn’t covered by health insurance in Germany, and non-prescription use of the HIV preventive is common. But is it safe?

A survey of MSM and transgender women found that diverse formulations and regimens for PrEP, such as long-acting injectables and “on-demand” PrEP, could increase uptake and persistence.